Hepatitis B Virus | China In-Depth | China | 2023
The prevalence of HBV is a major public health concern in China. Patients chronically infected with HBV are at high risk of developing hepatic cirrhosis and hepatocellular carcinoma. The majority of HBV patients are generally treated with established drugs such as pegylated interferon α-2a (Pegasys), pegylated interferon α-2b (Peg-Intron), tenofovir disoproxil fumarate (Viread), and entecavir (Baraclude). The primary market drivers include the recent launch of tenofovir amibufenamide (Jiangsu Hansoh’s HengMu) and the continued uptake of tenofovir alafenamide (Gilead’s Vemlidy). Several more therapies are expected to launch during the 2022-2032 forecast period. The ongoing reforms in the regulatory and A&R landscape of China are expected to encourage multinational companies to enter this market.
- What is the diagnosed prevalence of HBV, and how are these patients treated today? Are there any differences in the management strategies in urban versus rural China?
- Which are the most commercially relevant drugs in this market and why?
- What are interviewed experts’ opinion of current treatment options? What are the key unmet needs in the management of HBV?
- What are the key market access considerations, and how likely are they to affect the uptake of emerging therapies for HBV?
- What are the key drivers and constraints in this market, and how will the market evolve over the next 10 years?
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
PRIMARY RESEARCH
Country-specific qualitative and quantitative insights based on 5 thought-leader interviews and surveys of 50 gastroenterologists and hepatologists.
EPIDEMIOLOGY
Diagnosed prevalence of hepatitis B virus in China, with urban and rural breakup. Clinically relevant and market-relevant drug-treatable populations.
FORECAST
10-year, annualized, drug-level sales and patient share of key hepatitis B virus therapies through 2032, based on primary and secondary market research to formulate bottom-up assumptions.
EMERGING THERAPIES
Phase III/PR: 2 drugs; Phase II: 5+ drugs; coverage of select preclinical and Phase I products
